ArticleHealth education journal2017
Evaluation of modified risk claim advertising formats for Camel Snus.
Article in Health education journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Effects of a Reduced Risk Claim on Adolescents' Smokeless Tobacco Perceptions and Willingness to Use.The Journal of adolescent health : official publication of the Society for Adolescent Medicine · 2023Trial
- Effects of modified risk tobacco product claims on consumer comprehension and risk perceptions of IQOS.Tobacco control · 2022Trial
- Perceptions about levels of harmful chemicals in e-cigarettes relative to cigarettes, and associations with relative e-cigarette harm perceptions, e-cigarette use and interest.Addiction (Abingdon, England) · 2023Article
- Perceived Truthfulness of Reduced Lung Cancer Risk Advertising Claims Influences Consumers' Intention to try and to Purchase Snus.Tobacco use insights · 2023Article
- Intention to purchase alternative tobacco products as a function of smoking status and responses to advertising, packaging, and sensory experiences.Addictive behaviors · 2022Article
- Exploring the implications of modified risk claim placement in tobacco advertising.Preventive medicine reports · 2021Article
- Development and validation of behavioral intention measures of an E-vapor product: intention to try, use, dual use, and switch.Health and quality of life outcomes · 2021Article
- Smokers' Exposure to Perceived Modified Risk Claims for E-Cigarettes, Snus, and Smokeless Tobacco in the United States.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2021Article
- Harm Perceptions and Beliefs about Potential Modified Risk Tobacco Products.International journal of environmental research and public health · 2021Article
- How did beliefs and perceptions about e-cigarettes change after national news coverage of the EVALI outbreak?PloS one · 2021Article
- Assessing comprehension and perceptions of modified-risk information for snus among adult current cigarette smokers, former tobacco users, and never tobacco users.Addictive behaviors reports · 2020Article
- Testing messages about comparative risk of electronic cigarettes and combusted cigarettes.Tobacco control · 2019Article
- Smokers' perceptions of risks and harm from snus relative to cigarettes: A latent profile analysis study.Addictive behaviors · 2019Article
- The Impact of E-Cigarette Warnings, Warning Themes and Inclusion of Relative Harm Statements on Young Adults' E-Cigarette Perceptions and Use Intentions.International journal of environmental research and public health · 2019Article
- Impact of modified risk tobacco product claims on beliefs of US adults and adolescents.Tobacco control · 2018Article
- Consortium on Methods Evaluating Tobacco: Research Tools to Inform US Food and Drug Administration Regulation of Snus.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Objectives: The US Food and Drug Administration (FDA) has regulatory authority for modified risk tobacco product advertising claims. To guide future regulatory efforts, we investigated how variations in modified risk claim advertisements influence consumer perceptions of product risk claims for Camel Snus. Methods: Young people and adults (15-65), including current, never, and former smokers, were randomised to view one of five Camel Snus print advertisements as part of a web-based survey. Four of the advertisements presented information related to nitrosamine content of snus using four formats: (1) text, (2) a bar chart, (3) a text/testimonial and (4) a bar chart/testimonial. The fifth format, used as a control, was a current advertisement for Camel Snus without the explicit claims made about nitrosamine content. After viewing advertisements for all products, participants were asked which product they would be most interested in trying. Results: Participants exposed to advertisements that contained an explicit reduced risk message agreed the advertising claim for that product posed fewer health risks than cigarettes. However, advertisements containing the reduced risk messages were also viewed as containing less truthful information and respondents were more sceptical of the information presented. Advertisement claim format was not associated with selecting snus over the other tobacco products, nor was it associated with purchase intentions. Conclusion: The results of this research indicate that consumers respond to reduced risk messages, though perhaps not in the direct way anticipated. We found no significant differences by advertisement format (numerical, graphical, testimonial).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.